Sugi Predict

Sugi Predict / Targets / RPTOR

RPTOR

Regulatory-associated protein of mTOR · Q8N122 · RPTOR on Sugi Atlas →

31,173 patent compounds predicted against RPTOR, 22,116 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL135767 SCHEMBL135767 0.75 17/20
SCHEMBL154745 SCHEMBL154745 0.75 17/20
SCHEMBL154746 SCHEMBL154746 0.75 17/20
Cc-115 Cc-115 (SCHEMBL135765) 0.72 17/20
SCHEMBL151975 SCHEMBL151975 0.69 17/20
SCHEMBL154325 SCHEMBL154325 0.69 17/20
SCHEMBL155833 SCHEMBL155833 0.69 17/20
SCHEMBL157649 SCHEMBL157649 0.69 17/20
SCHEMBL138444 SCHEMBL138444 0.56 17/20
SCHEMBL153800 SCHEMBL153800 0.76 16/20
SCHEMBL153801 SCHEMBL153801 0.76 16/20
SCHEMBL154386 SCHEMBL154386 0.76 16/20
SCHEMBL136142 SCHEMBL136142 0.75 16/20
SCHEMBL152773 SCHEMBL152773 0.75 16/20
SCHEMBL152774 SCHEMBL152774 0.75 16/20
SCHEMBL153831 SCHEMBL153831 0.75 16/20
SCHEMBL153832 SCHEMBL153832 0.75 16/20
SCHEMBL155714 SCHEMBL155714 0.75 16/20
SCHEMBL138204 SCHEMBL138204 0.74 16/20
SCHEMBL138084 SCHEMBL138084 0.72 16/20

Clinical trials — most relevant to RPTOR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas PHASE2COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis PHASE1/PHASE2COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas PHASE2COMPLETED
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases PHASE1ACTIVE_NOT_RECRUITING
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PHASE1WITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC nanCOMPLETED
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) nanRECRUITING
Intermittent Fasting for Pancreatitis nanNOT_YET_RECRUITING
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) nanRECRUITING
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation nanCOMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RPTOR binder may also engage these)

ProteinNameSimilarity
Q8K4Q0 — 0.999 Q8K4Q0 →
Q9Y4J8 — 0.979 Q9Y4J8 →
Q6GQW0 — 0.971 Q6GQW0 →
Q13330 — 0.971 Q13330 →
O60941 — 0.970 O60941 →
Q62599 — 0.970 Q62599 →
Q9ERA0 — 0.970 Q9ERA0 →
Q9D2N4 — 0.969 Q9D2N4 →
Q8K4B0 — 0.968 Q8K4B0 →
P42230 — 0.967 P42230 →
A6QL63 — 0.967 A6QL63 →
Q2IBD0 — 0.967 Q2IBD0 →
Q2PG42 — 0.967 Q2PG42 →
Q09YI5 — 0.966 Q09YI5 →
STAT5B Signal transducer and activator of transcription 5B 0.966 landscape →
Q7Z3J2 — 0.966 Q7Z3J2 →
Q99M96 — 0.966 Q99M96 →
Q6ZUT9 — 0.966 Q6ZUT9 →
P52632 — 0.966 P52632 →
F1LTE0 — 0.965 F1LTE0 →
Q108U3 — 0.965 Q108U3 →
Q07E08 — 0.965 Q07E08 →
AP2A1 AP-2 complex subunit alpha-1 0.965 landscape →
Q62771 — 0.965 Q62771 →
Q07DW9 — 0.965 Q07DW9 →
P42231 — 0.964 P42231 →
A2RSQ0 — 0.964 A2RSQ0 →
Q6NZH6 — 0.964 Q6NZH6 →
Q2IBE0 — 0.964 Q2IBE0 →
Q00PJ0 — 0.964 Q00PJ0 →